Adverse event | Chloroquine subjects (%) | Placebo subjects (%) | P value |
---|---|---|---|
Total subjects with any event | 44 (76) | 39 (67) | 0.4107 |
Subjects with a serious adverse event | 5 (9) | 2 (3) | 0.4385 |
Total adverse events | 109 (100) | 105 (100) | – |
Infectious | 51 (47) | 42 (40) | 0.0609 |
Allergy/immunology | 5 (5) | 10 (10) | 0.2681 |
Musculoskeletal | 17 (16) | 15 (15) | 0.8357 |
CNS | 5 (5) | 3 (3) | – |
Psychiatric | 5 (5) | 6 (6) | – |
Hematologic/neoplasm | 2 (2) | 2 (2) | – |
Cardiovascular | 2 (2) | 3 (3) | – |
GI | 3 (3) | 3 (3) | – |
GU | 2 (2) | 2 (2) | – |
Metabolic | 1 (1) | 6 (6) | – |
Miscellaneous | 0 (0) | 3 (3) | – |
Ocular | 16 (15) | 10 (10) | 0.2654 |
Ocular details | |||
 Retinal | 3 | 3 | – |
 Lens | 4 | 2 | – |
 Vision | 2 | 0 | – |
 Infectious | 2 | 0 | – |
 Glaucoma | 2 | 2 | – |